[Therapy of pancreatic carcinoma with the monoclonal antibody BW 494/32: first clinical results].
In a phase-I clinical trial the monoclonal antibody BW 494/32 was administered to 18 patients with advanced pancreatic cancer of ductal origin. This murine immunoglobulin mediates an ADCC. The majority of patients tolerated this treatment without any side effects. There were no tumor remissions. 12 patients showed a progression of their pancreatic carcinoma after therapy. A stable course of the disease was observed in 6 patients for at least 3 months after therapy.
Friess
H
H
Abteilung für Allgemeine Chirurgie, Universität Ulm.
Büchler
M
M
Schulz
G
G
Beger
H G
HG
D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000920:Antibody-Dependent Cell Cytotoxicity; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000000981:diagnostic imaging / Q000276:immunology / Q000628:therapy*; D011877:Radionuclide Imaging
D000911:Antibodies, Monoclonal
Therapie des Pankreaskarzinoms mit dem monoklonalen Antikörper BW 494/32: erste klinische Ergebnisse.